.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AC04_Posaconazole.Posaconazole_1 .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AC04_Posaconazole.Posaconazole_1| name: | Posaconazole_1 |
| ATC code: | J02AC04_1 | route: | intravenous |
| n-compartments | 2 |
Posaconazole is a triazole antifungal agent approved for the prevention and treatment of invasive fungal infections caused by Aspergillus and Candida species in immunocompromised patients. It is used both for prophylaxis in patients at high risk for fungal infections and for treatment of ongoing invasive infections. Approved by FDA and widely used in clinical practice.
Healthy adult volunteers, single-dose pharmacokinetics following 200 mg intravenous infusion over 30 minutes.
Chen, L, et al., & Brüggemann, RJM (2020). Pharmacokinetics and Pharmacodynamics of Posaconazole. Drugs 80(7) 671–695. DOI:10.1007/s40265-020-01306-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/32323222
Sime, FB, et al., & Roberts, JA (2019). Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. Critical care (London, England) 23(1) 205–None. DOI:10.1186/s13054-019-2483-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31171022
Ding, Q, et al., & Pei, Q (2022). A Review of Population Pharmacokinetic Models of Posaconazole. Drug design, development and therapy 16 3691–3709. DOI:10.2147/DDDT.S384637 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36277600